Alkermes Nears FDA Ruling For Its Bipolar Treatment With Key Endorsement; ALKS Stock JumpsInvestors Business Daily • 10/12/20
FDA Advisory Committee Votes in Support of ALKS 3831 for the Treatment of Schizophrenia and Bipolar I DisorderPRNewsWire • 10/09/20
Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831PRNewsWire • 10/07/20
Alkermes Presents New Clinical Data on ALKS 4230 in Mini Oral Presentation at 2020 European Society for Medical Oncology (ESMO) Virtual CongressPRNewsWire • 09/18/20
Alkermes to Present New Data on Investigational Immuno-Oncology Candidate, ALKS 4230, at the 2020 European Society for Medical Oncology (ESMO) Virtual CongressPRNewsWire • 09/08/20
Virtual FDA Advisory Committee Meeting to Review New Drug Application for ALKS 3831 for Treatment of Schizophrenia and Bipolar I Disorder Tentatively Scheduled for Oct. 9, 2020PRNewsWire • 08/21/20
Alkermes Initiates Phase 2 Study Designed to Evaluate Clinical and Immunologic Activity of ALKS 4230 on Tumor Microenvironment in Patients with Advanced Solid TumorsPRNewsWire • 08/19/20
Alkermes plc (ALKS) CEO Richard Pops on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 07/29/20
Alkermes plc Reports Second Quarter 2020 Financial Results and Issues 2020 Financial ExpectationsPRNewsWire • 07/29/20
Do Options Traders Know Something About Alkermes (ALKS) Stock We Don't?Zacks Investment Research • 06/30/20
Alkermes Announces Launch of 3rd Annual Alkermes Pathways Research Awards® ProgramPRNewsWire • 06/29/20
Alkermes Awards COVID-19 Relief Fund Grants to 10 Innovative Programs Designed to Address Challenges for Patient CommunitiesPRNewsWire • 06/24/20
Alkermes (ALKS) Up 21.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 05/29/20
Alkermes Highlights New Data From Schizophrenia Portfolio at the American Society of Clinical Psychopharmacology 2020 Annual MeetingPRNewsWire • 05/27/20